Eversept Partners LP Invests $7.30 Million in Ultragenyx Pharmaceutical Inc. $RARE

Posted by Brian Himes on Jun 18th, 2026

Eversept Partners LP purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 317,182 shares of the biopharmaceutical company’s stock, valued at approximately $7,295,000.

Other large investors also recently made changes to their positions in the company. Assetmark Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares in the last quarter. Huntington National Bank boosted its stake in shares of Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares in the last quarter. Danske Bank A S bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth about $39,000. Smartleaf Asset Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,169 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter worth about $56,000. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Up 8.3%

Shares of NASDAQ:RARE opened at $26.91 on Thursday. The business has a 50 day moving average price of $24.17 and a 200 day moving average price of $24.91. Ultragenyx Pharmaceutical Inc. has a twelve month low of $18.29 and a twelve month high of $42.37. The company has a market cap of $2.65 billion, a price-to-earnings ratio of -4.40 and a beta of 0.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The business had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.19 million. During the same quarter in the previous year, the company earned ($1.57) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was down 2.2% compared to the same quarter last year. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -4.53 EPS for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 4,653 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $23.77, for a total value of $110,601.81. Following the completion of the sale, the chief financial officer owned 105,689 shares in the company, valued at approximately $2,512,227.53. This trade represents a 4.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Shehnaaz Suliman sold 5,740 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the completion of the sale, the director owned 27,951 shares of the company’s stock, valued at $702,129.12. This represents a 17.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 24,002 shares of company stock worth $575,039 over the last 90 days. Insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. The Goldman Sachs Group downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $61.00 to $25.00 in a research note on Tuesday, March 24th. Wells Fargo & Company upped their price target on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. JPMorgan Chase & Co. decreased their target price on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a research note on Thursday, March 12th. Finally, Cantor Fitzgerald increased their target price on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a research note on Thursday, May 21st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $59.56.

Read Our Latest Stock Analysis on Ultragenyx Pharmaceutical

About Ultragenyx Pharmaceutical

(Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.